MGXHealthcare · BiotechnologyThe 5 Wall Street analysts covering Metagenomi Therapeutics, Inc. hold a median 12-month price target of $7 — +757.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 22 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Metagenomi Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (85): The share count has been shrinking and the company is not leaning on new borrowing.
Value (14): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +757.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | Wells Fargo | Maintains | Overweight | $9.00 → $7.00 |
| 7 July 2026 | Chardan Capital | Maintains | Buy | $7.00 → $5.00 |
| 7 July 2026 | Chardan Capital | Maintains | Buy | — |
| 12 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 19 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 14 Aug 2025 | Wells Fargo | Maintains | Overweight | — |
| 15 May 2025 | Chardan Capital | Maintains | Buy | — |
| 14 May 2025 | Wells Fargo | Maintains | Overweight | — |
| 3 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2025 | Wells Fargo | Maintains | Overweight | — |
| 10 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 15 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Sept 2024 | Chardan Capital | Maintains | Buy | — |
| 21 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Aug 2024 | Chardan Capital | Maintains | Buy | — |
| 15 Aug 2024 | BMO Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MGX appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Metagenomi Therapeutics, Inc. returned −71.7% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 48% of US stocks
Cheaper than 87% of US stocks
Cheaper than 59% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 99% of US stocks
Higher than 30% of US stocks
Higher than 19% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Metagenomi Therapeutics, Inc. has a market value of $31.3M and an enterprise value of −$51.6M.
Revenue in the twelve months to 30 June 2026: $13.6M. The latest quarter shrank 120.6% year on year.
Net income over the same four quarters: −$93.5M, a −689.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$85.8M.
Trailing P/E: −0.4×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Metagenomi Therapeutics, Inc. employs 113 people — $120K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Metagenomi Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Metagenomi Therapeutics announced that Jian Irish, Ph.D., will participate in the Chardan 10th Annual Healthcare Conference.
Why it matters — The announcement concerns MGX’s participation in a healthcare industry conference.
Metagenomi Therapeutics, Inc. announced that Jian Irish, Ph.D., will present at the Wells Fargo 21st Annual Healthcare Conference. The presentation relates to the company's in vivo genome editing technologies aimed at developing curative genetic medicines.
Why it matters — An upcoming presentation at a major healthcare conference offers Metagenomi a platform to communicate about its gene editing programs to the investment community.
A law firm is urging Metagenomi Therapeutics, Inc. shareholders to contact them regarding potential breaches of fiduciary duties by company insiders, noting there may be limited time to enforce shareholder rights. The firm states it would handle the matter on a contingent fee basis with no out-of-pocket legal costs to shareholders.
Why it matters — MGX watchers would care because the notice signals a potential shareholder lawsuit or investigation into alleged insider misconduct, which could affect the company's legal and reputational standing.
Metagenomi Therapeutics reported a quarterly loss of $0.73 per share for Q2, which was wider than the Zacks Consensus Estimate of a $0.63 loss. This compares with a loss of $0.54 per share in the same period a year ago, meaning its revenue fell short of estimates.
Why it matters — MGX watchers would care because the company posted a larger-than-expected quarterly loss and missed revenue estimates, indicating weaker-than-anticipated financial performance for the period.
The 5 Wall Street analysts covering Metagenomi Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Metagenomi Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Metagenomi Therapeutics, Inc. 29 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Oct 2026, Metagenomi Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (85 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +757.6% from the last close, and Ticker Nerd's factor model ranks Metagenomi Therapeutics, Inc. 29 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Metagenomi Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $9 over the next 12 months.
Metagenomi Therapeutics, Inc. returned -71.7% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Metagenomi Therapeutics, Inc. is a precision genetic medicines company focused on in vivo genome editing for the development of curative therapies.
The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference". Metagenomi Therapeutics announced that Jian Irish, Ph.D., will participate in the Chardan 10th Annual Healthcare Conference.
Metagenomi Therapeutics, Inc. is a precision genetic medicines company focused on in vivo genome editing for the development of curative therapies. The company uses a proprietary metagenomics-derived toolbox to discover and engineer genome-editing systems, including nucleases, base editors, and gene-integration technologies. Its platform is designed to support precise DNA changes across a wide range of genetic targets, with current work centered on therapeutic programs for serious inherited conditions such as hemophilia and other genetic diseases. Metagenomi Therapeutics also collaborates with partners in biotechnology and pharmaceutical research to expand the potential uses of its editing technologies. Headquartered in Emeryville, California, Metagenomi Therapeutics, Inc. plays a role in the growing field of next-generation genetic medicine, where genome editing is being developed as a foundational approach to treating disease at its source.
CEO Dr. Jian Irish M.B.A., Ph.D. · 113 employees · United States · https://metagenomi.co
